- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02667288
An Open-Label Safety Study of A-101 Solution
An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Malvern, Pennsylvania, United States, 19355
- Aclaris Therapeutics, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is at least 18 years of age
- Clinical diagnosis of stable clinically typical seborrheic keratosis
Subject has 4 appropriate seborrheic keratosis Target Lesions on the trunk, extremities and face that each are eligible for treatment as defined below:
- Have a clinically typical appearance
- Have a PLA of 2 or greater and be a discrete lesion
- Not be covered with hair which, in the investigator's opinion, would interfere with the study medication treatment or the study evaluations
- Not be in an intertriginous fold
- Not be on the eyelids
- Not be within 5mm of the orbital rim
- Not be pedunculated
- If the subject is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an active method of birth control for the duration of the study
- Subject is non-pregnant and non-lactating
- Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of any Target Lesion or which exposes the subject to an unacceptable risk by study participation
- Subject is willing and able to follow all study instructions and to attend all study visits
- Subject is able to comprehend and willing to sign an Informed Consent Form.
Exclusion Criteria:
- Subject has clinically atypical and - or rapidly growing seborrheic keratosis lesions
- Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Lesser -Trelat)
- Subject has a current systemic malignancy
Subject has used any of the following systemic therapies within the specified period prior to enrollment:
- Retinoids; 180 days
- Glucocortico-steroids;
- Anti-metabolites (e.g., methotrexate);
Subject has used any of the following topical therapies within the specified period or in a proximity to any Target Lesion, that in the investigator's opinion interferes with the study medication treatment or the study assessments:
- LASER, light or other energy based therapy (e.g., intense pulsed light, photo-dynamic therapy;
- Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-flurouracil, or ingenol mebutate;
- Retinoids;
- Microdermabrasion or superficial chemical peels;
- Glucocortico-steroids or antibiotics
Subject currently has or has had any of the following within the specified period or in a proximity to any Target Lesion that, in the investigator's opinion, interferes with the study medication treatment or the study assessments:
- A cutaneous malignancy;
- A sunburn; currently
- A pre-malignancy (e.g., actinic keratosis); currently
- Body art (e.g., tattoos, piercing, etc.); currently
- Excessive tan; currently
- Subject has a history of sensitivity to any of the ingredients in the study medications
- Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations
- Subject has participated in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A-101 Solution
A-101 Solution 40% administered once
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Subjects With Lesion Clearance
Time Frame: Study day 148
|
Proportion of subjects for whom all target lesions were judged to be clear on the Physician Lesion Assessment (PWA) Scale.
The PWA scale is a 4 point scale used by the investigator to assess each subject target SK Lesion.
|
Study day 148
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Per Subject Percent of Lesion Clearance
Time Frame: Day 148
|
Physician Lesion Assessment (PWA) average Per-Subject Percent of target lesions judged to be clear at Visit 12 in the per protocol population.
The PWA scale is a 4 point scale used by the investigator to assess the subject's Target SK lesions.
|
Day 148
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Stuart D Shanler, MD, Aclaris Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-101-SEBK-303
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seborrheic Keratosis
-
Aclaris Therapeutics, Inc.CompletedSeborrheic Keratosis (SK)United States
-
PeplinCompletedSeborrheic KeratosisAustralia
-
DermBiont, Inc.RecruitingA Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic KeratosisSeborrheic KeratosisUnited States
-
University of California, DavisCompleted
-
DermBiont, Inc.Zepeda DermatologiaActive, not recruitingSeborrheic KeratosisEl Salvador
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Milton S. Hershey Medical CenterCompletedSeborrheic KeratosisUnited States
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Pulse Biosciences, Inc.CompletedSeborrheic Keratosis | Lesion SkinUnited States
-
Indonesia UniversityCompletedSeborrheic Keratosis | AcrochordonIndonesia
Clinical Trials on A-101 Solution
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Aclaris Therapeutics, Inc.Completed
-
Aclaris Therapeutics, Inc.CompletedCommon WartUnited States
-
Aclaris Therapeutics, Inc.Completed
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Aclaris Therapeutics, Inc.CompletedDermatosis Papulosa NigraUnited States
-
Aclaris Therapeutics, Inc.CompletedSeborrheic Keratosis (SK)United States
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
10xBio, LLCActive, not recruitingSubmental FatUnited States